Industry Roundup: J&J Supreme Court Petition, Ostroff Talks Supplement Regulation
This article was originally published in The Tan Sheet
Executive Summary
Supreme Court denies J&J petition in Motrin litigation; FDA chews on latest spiked supplement finding; Ostroff touts supplement market regulation; and more news in brief.
You may also be interested in...
CRN Promotes Counsel, Marketing And Regulatory Directors, Adds Legal, Communications Staff
Megan Olsen moves up to general counsel/senior VP, Gretchen Powers to marketing/member experience VP, Haiuyen Nguyen to regulatory/nutrition policy VP and Tammie Betway to office director/executive assistant to president/CEO. CRN also adds Daniel Garza as legislative/legal assistant and Elise Hall as communications assistant.
J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation
Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.